Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims are consistent with the provided QUESTRAN (cholestyramine) label excerpts (notably that cholestyramine is used adjunctively to lower elevated serum cholesterol LDL when diet is inadequate, and that it is indicated for pruritus with partial biliary obstruction). Claims about “different brand names” and “generics” are not addressed in the provided label excerpts.
Category Scores
Accurate Statements
Cholestyramine is a bile acid sequestrant.
Supported by label clinical pharmacology excerpt: QUESTRAN resin adsorbs and combines with bile acids in the intestine to form an insoluble complex.
Cholestyramine is used to help lower cholesterol.
Supported by Indications: adjunctive therapy to diet for reduction of elevated serum cholesterol in primary hypercholesterolemia; may lower LDL cholesterol and has variable effect in certain biliary conditions.
Cholestyramine is used to treat certain bile-acid–related conditions.
Supported by Indications: relief of pruritus associated with partial biliary obstruction (bile-acid/bile obstruction-related). Also notes partial biliary obstruction relevance in clinical pharmacology.
Unsupported Statements
Questran's generic (active ingredient) name is cholestyramine.
The provided FDA label excerpts do not explicitly state that “Questran’s generic name is cholestyramine.” The prompt identifies the active ingredient as cholestyramine, but that fact is outside the excerpted label text and is not directly supported by the supplied prescribing-information excerpts.
Cholestyramine can be sold under different brand names.
The provided labeling excerpts do not address brand-name availability beyond QUESTRAN and QUESTRAN LIGHT/Powder product naming.
Cholestyramine can be sold as generics.
The provided labeling excerpts do not address whether cholestyramine is sold as generics.
The generic name remains cholestyramine.
The provided labeling excerpts do not discuss generic naming/availability.
Contradictions
Important Omissions
No evaluation was possible for contraindications, boxed warnings, dosage/administration, safety precautions, drug interactions, monitoring, or adverse reactions because the AI claims provided did not include those topics.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The supported claims relate to general indication/mechanism (cholesterol lowering; pruritus in partial biliary obstruction). Unsupported statements concern branding/generic availability rather than dosing or safety-critical contraindications.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims about generic/brand availability are not supported by the provided prescribing-information excerpts.
Suggested Improvement
Limit claims to label-supported information: indications (adjunctive diet for elevated LDL cholesterol; pruritus with partial biliary obstruction) and the bile-acid binding mechanism. Remove or rephrase generic/brand availability statements unless supported by the provided label text.